Ariad Pharmaceuticals's victory against Lilly on NF-κB patent infringement has drug companies and legal experts wondering about the future of biotech patenting. Ken Garber reports on the aftermath of the surprising decision.
This is a preview of subscription content, log in via an institution to check access.
References
Epinat, J.C. & Gilmore, T.D. Oncogene 18, 6896–6909 (1999).
Begley, S. & Johannes, L. Wall Street Journal, June 26, 2002, p. B1
Garber, K. Nat. Biotechnol. 24, 127–130 (2006).
Pande, V. & Ramos, M.J. Curr. Med. Chem. 12, 357–374 (2005).
Loop, T. & Pahl, H. In Nuclear Factor κB (ed., Beyaert, R.) 1–48 (Kluwer Academic Publishers, Dordrecht, 2003).
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
https://doi.org/10.1038/Nat.Biotechnol24,127–130,(2006)
https://doi.org/10.1038/News@Nature24,249-251
https://doi.org/10.1038/News@Nature4,8-8(01Jan2005)
Web links
Rights and permissions
About this article
Cite this article
Garber, K. Patently absurd?. Nat Biotechnol 24, 737–739 (2006). https://doi.org/10.1038/nbt0706-737
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0706-737
- Springer Nature America, Inc.
This article is cited by
-
Patent watch
Nature Reviews Drug Discovery (2009)
-
Ariad's NFκB patent claims shot down on appeal
Nature Biotechnology (2009)